| Literature DB >> 25386047 |
Po-Len Liu1, Jung-Tung Liu2, Hsuan-Fu Kuo3, Inn-Wen Chong4, Chong-Chao Hsieh5.
Abstract
Proliferation of vascular smooth muscle cells (VSMCs) triggered by inflammatory stimuli and oxidative stress contributes importantly to atherogenesis. The association of green tea consumption with cardiovascular protection has been well documented in epidemiological observations, however, the underlying mechanisms remain unclear. This study aimed to elucidate the effects of the most active green tea catechin derivative, (-)-epigallocatechin-3-gallate (EGCG), in human aortic smooth muscle cells (HASMCs), focusing particularly on the role of a potent anti-inflammatory and antioxidative enzyme heme oxygenase-1 (HO-1). We found that pretreatment of EGCG dose- and time-dependently induced HO-1 protein levels in HASMCs. EGCG inhibited interleukin- (IL-)1β-induced HASMC proliferation and oxidative stress in a dose-dependent manner. The HO-1 inducer CoPPIX decreased IL-1β-induced cell proliferation, whereas the HO-1 enzyme inhibitor ZnPPIX significantly reversed EGCG-caused growth inhibition in IL-1β-treated HASMCs. At the molecular level, EGCG treatment significantly activated nuclear factor erythroid-2-related factor (Nrf2) transcription activities. These results suggest that EGCG might serve as a complementary and alternative medicine in the treatment of these pathologies by inducing HO-1 expression and subsequently decreasing VSMC proliferation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25386047 PMCID: PMC4214103 DOI: 10.1155/2014/523684
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Chemical structure of (−)-epigallocatechin-3-gallate (EGCG), the most abundant and most active catechin derivative from green tea.
Figure 2EGCG (a) dose- and (b) time-dependently induces HO-1 protein expression in HASMCs. Data are expressed as mean ± SD of three independent experiments. * P < 0.05 compared with medium alone condition.
Figure 3EGCG dose-dependently inhibits (a) cell proliferation and (b) ROS production in IL-1β-treated HASMCs. Data are expressed as mean ± SD of three independent experiments. * P < 0.05 versus control group; # P < 0.05 versus IL-1β-treated group.
Effect of EGCG on the cell cycle distribution in IL-1β-treated HASMCs.
| Phase | IL-1 | EGCG + IL-1 |
|
|---|---|---|---|
| Sub-G1 | 2.2% ± 1.1% | 3.7% ± 1.2% | 0.186 |
| G0/G1 | 54.2% ± 7.9% | 75.4% ± 8.3% | 0.033∗ |
| S | 31.6% ± 5.3% | 11.3% ± 4.3% | 0.007∗ |
| G2/M | 12.0% ± 2.3% | 9.6% ± 2.5% | 0.288 |
* P < 0.05.
The GSH and TBARS levels in EGCG and IL-1β-treated HASMCs.
| IL-1 | EGCG + IL-1 |
| |
|---|---|---|---|
| GSH | 27.3 ± 2.4 | 42.5 ± 3.5 | 0.003∗ |
| TBARS | 7.2 ± 1.4 | 3.4 ± 1.8 | 0.045∗ |
* P < 0.05.
Figure 4CoPPIX and ZnPPIX modulate proliferation inhibitory effect of EGCG in IL-1β-treated HASMCs. Data are expressed as mean ± SD of three independent experiments. * P < 0.05 versus control group; # P < 0.05 versus IL-1β-treated group; + P < 0.05 versus EGCG and IL-1β-treated group.
Figure 5Effect of EGCG on Nrf-2 activation. Data are expressed as mean ± SD of three independent experiments. * P < 0.05 versus control group.